Publications by authors named "David Yoho"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

81

Total Likes

101

Extended Reach

810,506

Social Features

30
E
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Sahil Khanna, Maha Assi, Christine Lee, David Yoho, Thomas Louie, Whitfield Knapple, Humberto Aguilar, Julia Garcia-Diaz, Gary P Wang, Scott M Berry

Drugs· October 2022

Videos about Article: user

1 29 4 51

View All Article and Social Media Activity
P
Prevention of recurrent infection by fecal microbiota, live-jslm (REBYOTA) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial.
Sahil Khanna, David Yoho, Daniel Van Handel, Brian J Clark, Tahany Awad

Therap Adv Gastroenterol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy for prevention of recurrent infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial.
Sahil Khanna, David Yoho, Daniel Van Handel, Brian J Clark, Tahany Awad

Therap Adv Gastroenterol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy under enforcement discretion for the prevention of recurrent infection.
Whitfield L Knapple, David S Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt

Therap Adv Gastroenterol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) Administered Under Enforcement Discretion to Patients With Infection.
Paul Feuerstadt, Adam Harvey, David S Yoho, Julia B Garcia-Diaz, Whitfield L Knapple

Open Forum Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Sahil Khanna, Maha Assi, Christine Lee, David Yoho, Thomas Louie

Drugs· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Robert Orenstein, Erik R Dubberke, Sahil Khanna, Christine H Lee, David Yoho

BMC Infect Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis